kenitinib

Kenitinib (also known as TSN222) is an orally bioavailable small molecule inhibitor of Bruton's tyrosine kinase (BTK) developed by Teligene. It is designed to treat various B-cell malignancies by disrupting the B-cell receptor (BCR) signaling pathway, which is essential for the growth and survival of neoplastic B cells. The drug is currently undergoing exploratory clinical evaluation in patients with relapsed or refractory B-cell lymphomas, with specific cohorts focusing on primary central nervous system lymphoma (PCNSL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). As a BTK inhibitor, kenitinib aims to provide a targeted therapeutic option for patients who have failed prior lines of therapy.

Other names

克耐替尼kenitinib